Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib


Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET

Aim(s): To explore Choi as an appropriate response assessment method in PNET treated with sunitinib.

Materials and methods: 17 patients with advanced PNET treated with sunitinib were evaluated by Computed Tomography (CT) using CHOI and RECIST, every 3 months. According to Choi criteria, partial response (PR) was defined as ≥10% decrease in size or ≥15% decrease in attenuation.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Solis Hernandez P

Authors: Solis Hernandez M, Calvo-Temprano D, Jiménez-Fonseca P, Faez L, Ruiz A,

Keywords: sunitinib, PNET, Choi, RECIST,

To read the full abstract, please log into your ENETS Member account.